AdvanCell
AdvanCell is a vertically integrated radiopharmaceutical company developing targeted alpha therapies for people with hard-to-treat cancers.
Founded
2019AdvanCell is a vertically integrated radiopharmaceutical company developing targeted alpha therapies for people with hard-to-treat cancers.
advancell.com.auCrawled Oct 16, 2026
The page lists Anna Karmann, Shahneen Sandhu, Louise Emmett, Oliver Sartor, Clemens Kratochwil, Stephen Rose and Ken Herrmann.
The page describes interest in 212Pb-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer and a phantom study showing that 212Pb SPECT imaging is feasible using specified gamma emissions.
The page says radionuclide therapies using lutetium-177 have achieved success but are not curative, and patients eventually relapse. It describes targeted alpha therapies as more potent and targeted, with less unwanted damage.
NSW company develops bold new way to attack cancers
Source: Australian Government Australian Research Council
Advancell is a bronze sponsor of the 2022 AANMS theranostics course.
ADVANCELL Advancing therapies for the treatment of cancer: NSW Health Medical Devices Fund’s boost towards AdvanCell research & development
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing targeted alpha therapies.
AdvanCell names **Sean Cassidy** as its new **Chief Financial Officer**. Cassidy brings over **20 years of biotechnology experience** to support the company’s growth as it progresses toward **late-stage development and commercialization**. His leadership will aid AdvanCell’s expansion during a critical phase of its pipeline.
Sep 2026 · AdvanCellNews article
AdvanCell is presenting at upcoming investor and industry conferences to showcase its clinical-stage radiopharmaceutical therapies for cancer treatment. The company develops targeted alpha therapies aimed at advancing precision oncology solutions. Management will engage with stakeholders at select events to highlight progress in its pipeline.
Sep 2026 · AdvanCellNews article
AdvanCell presents updated Phase 1b trial data for **TheraPb**, its **212Pb-ADVC001** therapy targeting metastatic prostate cancer via PSMA. The results support a recommended Phase 2 dosage of **212Pb-ADVC001**, advancing the company’s lead candidate in clinical development. Findings will be shared at the **ESMO Congress 2026**, a key oncology conference.
Jul 2026 · AdvanCellNews article
AdvanCell secures **$315 million** in funding to develop a **prostate cancer radiopharmaceutical** as a competitor to Pluvicto. The company plans to expand its **U.S. manufacturing capabilities** to support production. The investment underscores growing competition in targeted prostate cancer therapies.
Jul 2026 · Brief PharmaNews article